Antiviral treatment of chronic hepatitis B virus infections:: the past, the present and the future

被引：63

作者：

Ferir, Geoffrey ^{[1
]}

Kaptein, Suzanne ^{[1
]}

Neyts, Johan ^{[1
]}

De Clercq, Erik ^{[1
]}

机构：

[1] Rega Inst, B-3000 Louvain, Belgium

来源：

REVIEWS IN MEDICAL VIROLOGY | 2008年 / 18卷 / 01期

关键词：

D O I：

10.1002/rmv.554

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN-alpha. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug-resistant virus strains and the appearance of serious side effects. In the last 10 years, hepatitis B treatment has made much progress. Several treatments are now licensed for the treatment of patients with chronic hepatitis B and others are under development. Here, we provide an overview of the potential and mode of action of anti-HBV agents that are currently available, and/or may become available in the near future. Foremost among these newer compounds are adefovir dipivoxil, entecavir and telbivudine. Copyright (c) 2007 John Wiley & Sons, Ltd.

引用

页码：19 / 34

页数：16

共 132 条

[1]

BALAKRISHNA PS, 1996, ANTIMICROB AGENTS CH, V40, P380

[2] THE AMINO-TERMINAL DOMAIN OF THE HEPADNAVIRAL P-GENE ENCODES THE TERMINAL PROTEIN (GENOME-LINKED PROTEIN) BELIEVED TO PRIME REVERSE TRANSCRIPTION [J].